Cite
HARVARD Citation
Heijerman, H. et al. (2019). Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 394 (10212), pp. 1940-1948. [Online].